Hypercholesterolemia
Conditions
Brief summary
A study to determine lipid changing effects of MK0524A when compared to niacin extended release (NIASPAN) and placebo.
Interventions
DRUGComparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks
DRUGMK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks
DRUGComparator : niacin / Duraton of Treatment: 4 Weeks
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients must be between the ages of 18 and 70 years * Female patients must be pre-menopausal women that have been surgically sterilized, not pregnant and/or not planning to become pregnant
Exclusion criteria
* Patient has a history of peptic ulcer or gout * Patient is sensitive to niacin or products containing niacin * Patient drinks more than 2 alcoholic drinks per day * Patient has certain heart disease, cancer, or is HIV positive
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the HDL-C raising efficacy of MK-0524A when compared with niacin extended release (NIASPAN) and placebo. | After 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| To asses the triglyceride-lowering effects of MK-0524A when compared with niacin extended release (NIASPAN) and placebo. | After 4 weeks |
Outcome results
None listed